Abstract
No public abstract is available from the verified source records.
Open public full textLeah A. Goldberg, James J. Yoon, Hannah Johnston, Marta B. Davidson, Alexa Siddon, Rory M. Shallis, Evan C. Chen, Madelyn Burkart, Timothy S. Oh, Sunil G. Iyer, Ellen Madarang, Chandrasekar Muthiah, Joshua Kassner, Guru Subramanian Guru Murthy, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Vikas Gupta, Kristen M. Pettit, Olatoyosi Odenike, John Cursio, Anand A. Patel
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
SOHO state of the art updates and next questions | accelerated phase of MPN: what it is and what to do about it
10.1016/j.clml.2023.01.011 · 2023
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia
10.3324/haematol.2023.283950 · 2025
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
10.1182/bloodadvances.2024012880 · 2024
Genomics of MPN progression
10.1182/hematology.2020000129 · 2020
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS
10.1080/17474086.2024.2422554 · 2024
Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations
10.1158/1078-0432.ccr-21-3467 · 2022
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib
10.1111/bjh.16709 · 2020
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors
10.1182/bloodadvances.2020001528 · 2020
IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: a multicentre experience
10.1111/bjh.19027 · 2023
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
10.1182/blood-2016-08-733196 · 2017
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
10.1016/j.leukres.2012.08.013 · 2012
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022
MIPSS70+ Version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis
10.1200/jco.2018.78.9867 · 2018
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
10.1038/s41408-018-0095-2 · 2018
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms
10.1182/blood-2018-03-785907 · 2018
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes
10.1182/bloodadvances.2018021469 · 2018
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
10.1182/bloodadvances.2018015875 · 2018
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
10.1002/ajh.24973 · 2018
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS
10.1182/bloodadvances.2020002621 · 2020
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN
10.1182/bloodadvances.2023011735 · 2024
No additional external references are available.